Winslow Evans & Crocker’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Winslow Evans & Crocker’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-13	Closed	-$2K	–	1377
2019 Q1	$2K	Hold	13	–	–	﹤0.01%	1293
2018 Q4	$2K	Hold	13	–	–	﹤0.01%	1073
2018 Q3	$2K	Hold	13	–	–	﹤0.01%	1084
2018 Q2	$2K	Hold	13	–	–	﹤0.01%	1096
2018 Q1	$854	Hold	13	–	–	﹤0.01%	1077
2017 Q4	$1.09K	Hold	13	–	–	﹤0.01%	1063
2017 Q3	$1.5K	Sell	13 -70	-84%	-$7.37K	﹤0.01%	1045
2017 Q2	$9.64K	Buy	+83	New	+$10.3K	﹤0.01%	926

Other funds holding BLCM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Winslow Evans & Crocker's BLCM Position: Q2 2019 in Review

Winslow Evans & Crocker sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2019, closing a stake of 13 shares — an estimated $2K sold.

Winslow Evans & Crocker first reported a position in BLCM in Q2 2017 and held it in 8 quarters. The position peaked at $9.64K in Q2 2017. 79 funds tracked by Wall St. Rank hold BLCM as of Q2 2019.

Winslow Evans & Crocker reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Winslow Evans & Crocker sold 13 Bellicum Pharmaceuticals, Inc. shares in Q2 2019, an estimated $2K.
Winslow Evans & Crocker first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2017 and held it in 8 quarters.
Winslow Evans & Crocker's Bellicum Pharmaceuticals, Inc. position peaked at $9.64K in Q2 2017.
79 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2019.

Based on Winslow Evans & Crocker's 13F filing for Q2 2019, filed 19 Jul 2019.